Results 21 to 30 of about 10,368 (131)
TAVI Through the Years: A Systematic Review of Progress
Journal of Pharmacy and Bioallied SciencesIntroduction: Transcatheter Aortic Valve Implantation (TAVI) has evolved over the years and now is being used in the management of patients with symptomatic severe aortic stenosis (AS) in categories of high, intermediate, and even low operative risk ...
Sahil Ahmad +5 more
doaj +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Atrial fibrillation (AF) is a frequent comorbidity in patients with severe aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). In addition, new‐onset AF can occur after TAVI. However, data on how AF affects outcomes in patients undergoing TAVI remain conflicting.
Kimberley I. Hemelrijk +23 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background Transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) anatomy remains challenging due to anatomical complexity and limited trial data. New‐generation balloon‐expandable valves, such as Myval, require further evaluation in this subgroup.
Balázs Magyari +11 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Aortic stenosis (AS) is associated with a heightened burden of cardiovascular comorbidities, atrial fibrillation (AF), and progressive valvular calcification, all of which may contribute to cerebrovascular events across the disease continuum.
Priyanka Boettger +7 more
wiley +1 more source
Prognostic impact of postprocedure stroke volume in patients with low-gradient aortic stenosis
Open Heart, 2019 Objective The effect of postoperative blood flow status on the prognosis of patients with low-gradient severe aortic stenosis (AS) has not been examined.
Yugo Nara +19 more
doaj +1 more source
Российский кардиологический журнал, 2023 Aim. To demonstrate the TAVISCORE program designed to stratify the risk of complications after aortic valve (AV) interventions in patients with reduced ejection fraction.Material and methods.
D. A. Strelkov +6 more
doaj +1 more source
Catheterization and Cardiovascular Interventions, EarlyView.ABSTRACT Background The EMPIRE I study assessed the early (30 days) safety and efficacy of a new fully repositionable delivery system (IMPERIA) for the commercially available ALLEGRA transcatheter aortic valve in patients with either severe native aortic stenosis or a degenerated surgical bioprosthesis.
José Antonio Baz +15 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
Current Directions in Biomedical EngineeringTranscatheter Aortic Valve Replacement (TAVR) is a widely used treatment for severe aortic stenosis, particularly in patients with a high surgical risk. Although initially designed for tricuspid aortic valves (TAV), its use in bicuspid aortic valves (BAV)
Supp Laura +6 more
doaj +1 more source